Background {#Sec1}
==========

Unintended treatment interruptions may lead to a prolongation of the prescribed overall treatment time. For radiotherapy with curative intent, prolongation of the prescribed overall treatment time has been linked to inferior clinical outcomes \[[@CR1]--[@CR3]\]. This association appears to be consistent across many disease sites including head and neck cancer, cervical cancer, lung cancer, breast cancer, and other cancers \[[@CR4], [@CR5]\]. Prospective and retrospective studies have shown that treatment prolongation can increase the risk of local recurrence by up to 2% per day for certain malignancies \[[@CR5]\].

The association between prolongation of the prescribed overall treatment time and inferior clinical outcomes has been explained with an accelerated repopulation of tumor clonogens, which can occur after treatment initiation \[[@CR6]\]. It has also been reported that noncompliance may serve as a behavioral biomarker for other risk factors that contribute to poor outcomes, such as noncompliance with other important clinician visits and procedures, lack of social support, and mood disorders \[[@CR4]\].

In this study, we analyzed the compliance to the prescribed radiotherapy schedule of breast cancer patients treated with postoperative radiotherapy of the whole breast or chest wall. The goal of the study was to identify factors significantly associated with the occurrence of treatment interruptions.

Patients and methods {#Sec2}
====================

Data collection and patient selection {#Sec3}
-------------------------------------

The electronic patient files of 286 consecutive unselected patients treated with adjuvant breast cancer radiotherapy between March 2014 and August 2016 were reviewed. Eligibility criteria for the analysis were (a) histologically proven diagnosis of breast cancer or carcinoma in situ and (b) treatment with adjuvant postoperative radiotherapy after breast-conserving surgery or mastectomy. Exclusion criteria were bilateral breast cancer or history of previous radiotherapy of the breast or chest wall.

Patients were treated with either conventional fractionation (CF; 28 daily fractions of 1.8 Gy or 25 fractions of 2.0 Gy) or hypofractionation (HF; 15 daily fractions of 2.67 Gy). Where indicated, an electron boost was applied (five or eight daily fractions of 2.0 Gy). Radiotherapy fractions were scheduled once per day and five times per week. Patients who missed radiotherapy fractions were offered to be treated on weekends in order not to exceed the prescribed overall treatment time. The radiation techniques used were inverse planned intensity-modulated radiotherapy (IMRT) or three-dimensional planned conformal radiotherapy using wedge compensation (3DCRT). The patients were thoroughly informed about the pros and cons of the two fractionation regimens and radiation techniques, and the treatment decision was mainly based on patient preference. Patients not covered, or not fully covered, by medical insurance tended to opt for 3DCRT for financial reasons. Patients with personal commitments limiting the overall treatment time or patients living far away from the radiotherapy facility tended to opt for HF.

The acute radiation reactions and reasons for treatment interruptions were documented prospectively in the Local Area Network Therapy Information System "Lantis" (Siemens Healthcare, Germany). The acute radiation reactions were assessed once weekly during radiotherapy and 6 weeks after radiotherapy by two observers using the Common Terminology Criteria for Adverse Events (CTCAE v4.03). The two observers were not involved in the statistical analysis of the study, and a table with all weekly assessments was included in the "End of Treatment Report" of all patients. The maximum acute radiation reaction observed during the full course of the radiotherapy (including the boost to the tumor bed if applied) was used for the statistical analysis. Treatment interruptions were defined as missing at least one of the scheduled daily radiotherapy fractions. The reasons for treatment interruptions were categorized into "public holidays," "patient unwillingness," "machine breakdown," "radiation reactions," and "unspecified," and documented prospectively together with the length of the treatment interruption.

The study was approved by the local institutional ethics committee and conducted in accordance with the Helsinki Declaration in its current version.

Treatment planning and radiation techniques {#Sec4}
-------------------------------------------

The treatment planning and radiation techniques used for this study have been described in detail elsewhere \[[@CR7]--[@CR9]\]. In short, a non-contrast computed tomography (CT) simulation with a slice thickness of 5 mm was performed with the patient in the supine position. The planning target volume (PTV) of the whole breast or chest wall was defined according to the recommendations of the breast cancer atlas for radiation therapy planning consensus definitions of the Radiation Therapy Oncology Group (RTOG) \[[@CR10]\]. The IMRT and 3DCRT plans were generated using the treatment planning system XIO 4.4 (CMS, Inc., St. Louis, Mo.). The dose to the PTV was prescribed according to the International Commission on Radiation Units and Measurement (ICRU) Reports 50 and 62 recommendations. Two Siemens Oncor Anvantgarde linear accelerators with a 160 MLC Multileaf Collimator were used for the treatment. Daily online verification and correction of the patient positioning error prior to radiotherapy were performed for all patients using orthogonal megavoltage electronic portal images \[[@CR11]\]. No respiratory gating \[[@CR12]--[@CR14]\], integrated boost \[[@CR15], [@CR16]\], or partial breast irradiation \[[@CR17]\] techniques were applied in this study. Two tangential semi-opposed beams, physical wedges (usually 15° or 30°), a 160 MLC Multileaf Collimator and 6 MV photons were used for the IMRT and 3DCRT plans. Occasionally a mixed-beam technique using 6 MV and 15 MV photons was used for the 3DCRT plans. Inverse treatment planning and a step-and-shoot technique were used for all IMRT plans. Tissue inhomogeneities were considered in the treatment planning optimization process, and the dose calculation algorithm used was "Superposition." A few patients with left-sided breast cancer and unfavorable thoracic geometry were treated with seven-field IMRT in order to reduce the high-dose region to the heart \[[@CR18]\].

Statistical analysis {#Sec5}
--------------------

Differences between patient groups stratified by the occurrence of treatment interruptions (Table 1) or by the fractionation regimen (Table 3) were assessed using the chi-square test or *t* test where appropriate. To assess the association of multiple factors with the occurrence of treatment interruptions, a univariate and multivariate logistic regression analysis was performed. The factors tested in the logistic regression analysis are listed in Table 2. The model selection of the multivariate analysis was performed by a backward stepwise strategy. All tests were two-sided, and a *p* value of ≤0.05 was considered significant.

Results {#Sec6}
=======

In total, 58 of 286 (20.3%) patients experienced treatment interruptions. The patient, disease, and treatment characteristics of the study population stratified by the occurrence of treatment interruptions are demonstrated in Table [1](#Tab1){ref-type="table"}. As expected, the mean age of the study population was considerably lower compared with reports from Europe or the United States, most likely due to the young age structure of the general population \[[@CR19]\].Table 1Patient, disease, and treatment characteristics stratified by occurrence of treatment interruptionsCharacteristicsTotalTreatment interruptions*p*YesNo*n*%*n*%*n*%Patients2861005820.322879.7--Country of originMiddle East20872.74272.416672.80.18Asia4214.7712.13515.4--Africa258.746.9219.2--Europe/USA113.858.662.6--Age at diagnosis (years)Mean (SD)48(9.6)48(8.9)49(9.8)0.65^a^Body mass index\<254716.51220.73515.40.5725--297626.71627.66026.4--≥3016256.83051.713258.1--Menopausal statusPremenopausal14350.03153.411249.10.56Postmenopausal14350.02746.611650.9--Marital statusMarried27094.45798.321393.40.15Single165.611.7156.6--Financial statusMedical insurance16357.03051.713358.30.36Cash12343.02848.39541.7--Distance from home to treatment facility (km)≤5018364.03967.214463.20.6551--1006221.71017.25222.8--\>1004114.3915.53214.0--PathohistologyInvasive ductal cancer26492.35391.421192.50.83Invasive lobular cancer155.246.9114.8--DCIS51.711.741.8--Other20.700.020.9--GradingG1227.7610.3167.00.31G29131.82034.57131.1--G314651.02441.412253.5--Not reported279.4813.8198.3--T classificationpTis62.123.441.80.92pT082.823.462.6--pT19834.32237.97633.3--pT211439.92237.99240.4--pT33010.546.92611.4--pT4207.046.9167.0--Not reported103.523.483.5--N classificationpN010235.72848.37432.50.20pN18429.41322.47131.1--pN26021.01220.74821.1--pN33311.546.92912.7--Not reported72.411.762.6--M classificationcM028298.658100.022498.20.31cM141.400.041.8--ER statusPositive20471.34374.116170.60.62Negative7124.81424.15725.0--Not reported113.811.7104.4--PR statusPositive18464.33763.814764.50.89Negative8630.11729.36930.3--Not reported165.646.9125.3--Her2/neu statusPositive7927.61729.36227.20.94Negative18865.73763.815166.2--Not reported196.646.9156.6--Planning target volume (PTV)Chest wall15052.42746.612353.90.31Whole breast13647.63153.410546.1--Volume of PTV (cm^3^)≤6527124.8915.56227.20.33653--8727225.21729.35524.1--873--12357124.81627.65524.1--≥12367225.21627.65624.6--Locoregional lymph nodes treated as part of planYes14952.12543.112454.40.12No13747.93356.910445.6--Boost to the tumor bedYes13346.53458.69943.40.04No15353.52441.412956.6--Radiotherapy techniqueTB-IMRT16758.43356.913458.80.803DCRT11941.62543.19441.2--Fractionation regimenCF14651.03967.210746.90.01HF14049.01932.812153.1--Number of fractions≤158630.11119.07532.90.0116--204515.7813.83716.2--21--287024.51119.05925.9--≥298529.72848.35725.0--ChemotherapyAdjuvant21173.84170.717074.60.58Neo-adjuvant6121.31525.94620.2--No chemotherapy144.923.4125.3--Hormone therapyYes21073.44475.916672.80.64No7626.61424.16227.2--Fatigue (grade CTCAE v4.0)010135.32441.47733.80.51117260.13153.414161.8--2134.535.2104.4--Dermatitis radiation (grade CTCAE v4.0)0113.823.493.90.37122879.74272.418681.6--24415.41322.43113.6--331.011.720.9--Dysphagia (grade CTCAE v4.0)020772.44781.016070.20.2617225.21017.26227.2--272.411.762.6--Esophagitis (grade CTCAE v4.0)026592.75187.921493.90.211207.0712.1135.7--210.300.010.4--Cough (grade CTCAE v4.0)026693.05493.121293.00.651175.946.9135.7--231.000.031.3--Dyspnea (grade CTCAE v4.0)027796.95696.622196.90.83182.823.462.6--210.300.010.4--*p*Values using chi-square testing to compare patient subgroups with and without treatment interruptions, except as indicated*DCIS* ductal carcinoma in situ, *ER* estrogen receptor, *PR* progesterone receptor, *TB-IMRT* tangential beam intensity-modulated radiotherapy, *3DCRT* three-dimensional conformal radiotherapy, *CF* conventional fractionation, *HF* hypofractionation, *CTCAE* Common Terminology Criteria for Adverse Events^a^Unpaired Student's *t* test

On univariate analysis, three of 23 tested factors were significantly associated with a higher risk of treatment interruptions (Table [2](#Tab2){ref-type="table"}). All three factors were related to longer treatment courses (CF, number of radiotherapy fractions ≥29, boost to the tumor bed). In total, 19 of 140 (13.6%) patients treated with HF and 39 of 146 (26.7%) treated with CF had treatment interruptions. On multivariate analysis, the only remaining independent significant prognostic factor was the fractionation regimen: CF vs. HF; *p* = 0.007; odds ratio (95% confidence interval) 2.3 (1.3, 4.2).Table 2Univariate logistic regression results for associations with treatment interruptionsCharacteristicsOdds ratioLower 95%CIUpper 95%CI*p*Country of originMiddle EastReferenceAsia1.330.434.080.62Africa1.270.533.050.60Europe/USA0.300.091.040.06Age at diagnosis (years)≤MeanReference\>Mean0.920.511.640.77Body mass index\<25Reference25--291.290.553.030.57≥301.510.703.250.29Menopausal statusPremenopausalReferencePostmenopausal1.190.672.120.56Marital statusMarriedReferenceSingle0.250.031.930.18Financial statusMedical insuranceReferenceCash payer0.770.431.360.36Commuting distance to treatment facility (km)≤50Reference51--1001.040.462.360.93\>1001.460.543.990.46Planning target volume (PTV)Chest wallReferenceWhole breast0.740.421.330.31Volume of PTV (cm^3^)≤652Reference653--8720.470.191.140.09873--12350.500.201.220.13≥12360.510.211.240.14Locoregional lymph nodes treated as part of planYesReferenceNo0.640.361.140.13Boost to the tumor bedYesReferenceNo1.851.033.310.04Radiotherapy techniqueIMRTReference3DCRT0.930.521.660.80Fractionation regimenCFReferenceHF2.321.274.26\<0.01Number of radiotherapy fractions≤15Reference16--200.680.251.830.4421--280.790.321.940.60≥290.300.140.65\<0.01ChemotherapyAdjuvantReferenceNeo-adjuvant0.740.381.450.38No chemotherapy1.450.316.720.64Hormone therapyYesReferenceNo1.250.642.440.51Fatigue (grade CTCAE v4.0)0Reference\>00.740.411.330.31Dermatitis radiation (grade CTCAE v4.0)0Reference\>01.150.245.480.86Dysphagia (grade CTCAE v4.0)0Reference\>00.550.271.130.10Esophagitis (grade CTCAE v4.0)0Reference\>02.100.815.460.13Cough (grade CTCAE v4.0)0Reference\>00.980.323.060.97Dyspnea (grade CTCAE v4.0)0Reference\>01.130.235.580.88Any acute radiation reaction (grade CTCAE v4.0)0, 1Reference2, 31.690.873.280.12*CI* confidence interval, *IMRT* intensity-modulated radiotherapy, *3DCRT* three-dimensional conformal radiotherapy, *CF* conventional fractionation, *HF* hypofractionation, *CTCAE* Common Terminology Criteria for Adverse Events

Concerning the reasons for treatment interruptions, no statistically significant differences were detected between the patients treated with CF and HF (Table [3](#Tab3){ref-type="table"}). However, treatment interruptions were on average longer for patients treated with CF (3.2 days vs. 2.3 days; *p* = 0.02; Table [3](#Tab3){ref-type="table"}).Table 3Reason for and length of treatment interruptions stratified by fractionation regimenReason for treatment interruptionsTotalFractionation regimen*p*HFCF*n*%*n*%*n*%Public holidaysYes3356.91157.92256.40.91No2543.1842.11743.6--Days, mean (SD)1.9(1.8)1.6(1.5)2.1(2.0)0.34^a^Patient unwillingnessYes2339.7842.11538.50.79No3560.31157.92461.5--Days, mean (SD)0.6(0.9)0.5(0.7)0.6(0.9)0.80^a^Machine breakdownYes813.815.3717.90.19No5086.21894.73282.1--Days, mean (SD)0.3(0.8)0.1(0.2)0.4(1.0)0.16^a^Radiation reactionsYes46.900410.30.15No5493.1191003589.7--Days, mean (SD)0.1(0.3)0(0)0.1(0.3)0.16^a^UnspecifiedYes11.715.3000.15No5798.31894.739100--Days, mean (SD)0.1(0.4)0.2(0.7)0(0)0.15^a^Treatment interruptionsYes5820.31913.63926.70.01No22879.712186.410773.3--For one reason4781.01789.53076.90.25For two reasons1119.0210.5923.1--Days, mean (SD)2.9(1.4)2.3(1.2)3.2(1.4)0.02^a^Prolongation of the prescribed overall treatment time after compensation for treatment interruptions0 days2441.4947.41538.50.681 day1525.9631.6923.1--2 days915.515.3820.5--3 days58.615.3410.3--4 days35.215.325.1--5 days23.415.312.6--*p*Values using chi-square testing to compare patient subgroups treated with HF or CF, except as indicated*CF* conventional fractionation, *HF* hypofractionation^a^Unpaired Student's *t* test

In accordance with our departmental policy, treatment interruptions were compensated by treating the corresponding patients on weekends within the prescribed overall treatment time. After compensation for treatment interruptions, eventually 41.4% of the patients with treatment interruptions completed their treatment within the prescribed overall treatment time, corresponding to 88.1% of the total study population. The remaining patients experienced a prolongation of the prescribed overall treatment time of 1--5 days (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec7}
==========

Our study shows that a significant proportion of our patients experienced unintended treatment interruptions (20.3%). The compliance to the prescribed radiotherapy schedule was significantly better with HF than with CF (patients with treatment interruptions; 13.6% vs. 26.7%). The data suggest that the better compliance was basically related to the shorter overall treatment time of HF (3--4 weeks) compared with CF (5--6.5 weeks).

Several randomized trials have shown that HF is equally effective in long-term disease control and late radiation effects compared with CF in adjuvant breast cancer radiotherapy \[[@CR20]--[@CR23]\]. The main motivation for developing protracted radiotherapy regimens was the benefit to patients and health services in terms of convenience and cost. Recent breast cancer studies suggested that HF is also associated with a significantly lower acute skin reaction rate compared with CF \[[@CR7], [@CR24], [@CR25]\]. Our study revealed another advantage of HF over CF: a significantly better patient compliance with the prescribed radiotherapy schedule.

Noncompliance with the prescribed radiotherapy schedule can have multiple deleterious effects. For postoperative radiotherapy of breast cancer, a prolongation of the overall treatment time of more than 1 week has been shown to decrease the 5‑year local control rate by 5% \[[@CR26]\]. The management of the increased number of recurrences may place additional burden on the health-care system. Disturbances in the clinical workflow by noncompliant ("no-show") patients occupying treatment slots on the linear accelerator may indirectly cause treatment delays for other patients and an extension of the work day. Compensation of missed radiotherapy fractions during the working week by additional treatment on weekends will further increase costs in terms of time and effort.

In a large study of 2184 patients receiving radiotherapy with curative intent for various malignancies in an American urban academic cancer center, 20.2% missed multiple radiotherapy fractions, 17.4% a single radiotherapy fraction, and 62.4% no radiotherapy fractions. The median number of missed treatments was 3. Similar to our study, the statistical analysis identified "prescribed longer radiotherapy courses" as a statistically significant independent predictor of noncompliance. The authors suggested that this finding may provide additional rationale for adopting shortened radiotherapy schedules as a means of improving patient adherence to prescribed therapy \[[@CR27]\]. Other predictors for noncompliance identified in the previously cited study were "particular cancer diagnoses," "low socioeconomic status," and "treatment during winter months." "Distance from the patients' home to the radiotherapy facility" \[[@CR28]--[@CR30]\] and "patients from households that lost family income" \[[@CR31]\] have been reported as predictors of noncompliance with the prescribed radiotherapy schedule by other study groups. It is likely that factors influencing compliance depend to a significant extent on individual circumstances like the location of the radiotherapy facility, infrastructure of the region, and socioeconomic status of the population, and may therefore vary between treatment facilities. However, in our study CF, which was the longer radiotherapy schedule compared with HF, was the only significant predictor of noncompliance on multivariate analysis of 23 factors.

The limitations of our study should be noted. Owing to the relatively limited patient number (*n* = 286), possible influencing factors may not have reached statistical significance. The socioeconomic and psycho-oncological status of the patients could not be evaluated because of lack of data. Moreover, owing to the retrospective nature of the study, a selection bias of patients treated with HF and CF cannot be excluded with certainty.

Despite all efforts to avoid a prolongation of the prescribed overall treatment time by thorough education of the patient and compensation of missed radiotherapy fractions by treatment on weekends, 34 of 286 patients (11.9%) in our study eventually experienced a moderate prolongation of the prescribed overall treatment time of 1--5 days. Data concerning the detrimental effect of treatment interruptions in adjuvant breast cancer radiotherapy are scarce. However, a significant decrease in the 5‑year local control rate after treatment interruptions of more than 1 week has been reported \[[@CR26]\].

Conclusion {#Sec8}
==========

A significant proportion of breast cancer patients in our study experienced treatment interruptions. Compliance with the prescribed radiotherapy schedule was significantly better for patients treated with HF than for those treated with CF. The data suggest that the better compliance is basically related to the shorter overall treatment time of HF (3--4 weeks) compared with CF (5--6.5 weeks). This finding may add to the treatment decision in favor of HF in particular in situations with expected lower compliance with longer radiotherapy schedules.
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